Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy. Results of the DRKS00004519 study of the East German Study Group

被引：0
|
作者：
Jaekel, N. [1 ]
Hubert, K. [2 ]
Krahl, R. [1 ]
Hanel, M. [3 ]
Maschmeyer, G. [4 ]
Herbst, R. [5 ]
Jakob, C. [4 ]
Schulze, S. [1 ]
Wang, S. -Y. [1 ]
Cross, M. [1 ]
Kahl, C. [6 ]
Wass, M. [2 ]
Sayer, H. G. [7 ]
Brosteanu, O. [8 ]
Niederwieser, D. [1 ]
Al-Ali, H. K. [2 ]
机构：
[1] Uniklin Leipzig, Hamatol & Internist Onkol, Leipzig, Germany
[2] Univ Klinikum Halle, Hamatol & Internist Onkol, Halle, Germany
[3] Klinikum Chemnitz, Hamatol & Internist Onkol, Chemnitz, Germany
[4] Klinikum Ernst Bergmann, Abt Hamatol Onkol, Potsdam, Germany
[5] Klinikum Chemnitz, Abt Hamatol Onkol, Chemnitz, Germany
[6] Klinikum Magdeburg, Abt Hamatol Onkol, Magdeburg, Germany
[7] HELIOS Klinikum Erfurt, Hamatol & Internist Onkol, Erfurt, Germany
[8] Zentrum Klin Studien Leipzig, Leipzig, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V133
引用
收藏
页码：27 / +
页数：2
相关论文
共 42 条
  • [1] RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS >60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP
    Jaekel, N.
    Hubert, K.
    Krahl, R.
    Haenel, M.
    Maschmeyer, G.
    Herbst, R.
    Jakob, C.
    Schulze, S.
    Wang, S. -Y.
    Cross, M.
    Kahl, C.
    Wass, M.
    Sayer, H.
    Brosteanu, O.
    Niederwieser, D.
    Al-Ali, H. K.
    HAEMATOLOGICA, 2017, 102 : 214 - 214
  • [2] Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy (RAS-AZIC): Results of the phase I of the DRKS00004519 study
    Jaekel, N.
    Hubert, K.
    Krahl, R.
    Cross, M.
    Niederwieser, D.
    Al-Ali, H. K.
    Oncology Research and Treatment, 2015, 38 : 47 - 47
  • [3] Response-adapted sequential Azacitidine and induction chemotherapy in patients > 60 years with newly diagnosed AML eligible for chemotherapy: Interim analysis of the DRKS00004519 study (RAS-AZIC)
    Jaekel, N.
    Hubert, K.
    Krahl, R.
    Haenel, M.
    Maschmeyer, G.
    Herbst, R.
    Jacob, C.
    Schulze, S.
    Wang, S. -Y
    Cross, M.
    Brosteanu, O.
    Niederwieser, D.
    Al-Ali, H. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 44 - 44
  • [4] RESPONSE-ADAPTED SEQUENTIAL AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS >60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY (RAS-AZIC): INTERIM ANALYSIS OF THE DRKS00004519 STUDY
    Jaekel, N.
    Hubert, K.
    Krahl, R.
    Haenel, M.
    Maschmeyer, G.
    Herbst, R.
    Jakob, C.
    Schulze, S.
    Wang, S. Y.
    Cross, M.
    Brosteanu, O.
    Niederwieser, D.
    Al-Ali, H. K.
    HAEMATOLOGICA, 2016, 101 : 326 - 327
  • [5] Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): Results of the Phase I of the DRKS00004519 Study
    Al-Ali, Haifa Kathrin
    Krahl, Rainer
    Cross, Michael
    Karolin, Hubert
    Jaekel, Nadja
    Niederwieser, Dietger
    BLOOD, 2014, 124 (21)
  • [6] Response -Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)
    Al-Ali, Haifa Kathrin
    Jaekel, Nadja
    Hubert, Karolin
    Krahl, Rainer
    Haenel, Mathias
    Maschmeyer, Georg
    Herbst, Regina
    Jakob, Christian
    Schultze, Susann
    Wang, Song-Yau
    Brosteanu, Oana
    Niederwieser, Dietger
    BLOOD, 2015, 126 (23)
  • [7] Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)
    Jaekel, Nadia
    Hubert, Karolin
    Haenel, Mathias
    Maschmeyer, Georg
    Herbst, Regina
    Schulze, Susann
    Wang, Song-Yau
    Kahl, Christoph
    Wass, Maxi
    Sayer, Herbert G.
    Brosteanu, Oana
    Niederwieser, Dietger
    Al-Ali, Haifa Kathrin
    BLOOD, 2018, 132
  • [8] Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)
    Jaekel, Nadja
    Schulze, Susann
    Siebolts, Udo
    Haak, Anja
    Pazaitis, Nikolaos
    Cross, Michael
    Niederwieser, Dietger
    Hanel, Mathias
    Maschmeyer, Georg
    Wass, Maxi
    Heukamp, Lukas
    Menon, Roopika
    Bertrand, Miriam
    Wickenhauser, Claudia
    Brosteanu, Oana
    Al-Ali, Haifa Kathrin
    BLOOD, 2019, 134
  • [9] Impact of somatic mutations on response in patients > 60 years old with newly diagnosed AML treated with responseadapted sequential Azacitidine and induction chemotherapy: results of the DRKS00004519 trial (RAS-AZIC) of the East German study group (OSHO)
    Jaekel, N.
    Schulze, S.
    Siebolts, U.
    Haak, A.
    Cross, M.
    Niederwieser, D.
    Haenel, M.
    Maschmeyer, G.
    Wass, M.
    Heukamp, L.
    Menon, R.
    Bertrand, M.
    Wickenhauser, C.
    Al-Ali, H. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 169 - 170
  • [10] Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients >60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)
    Jaekel, Nadia
    Hubert, Karolin
    Krahl, Rainer
    Haenel, M.
    Maschmeyer, Georg
    Herbst, Regina
    Jakob, Christian
    Schulze, Susann
    Wang, Song-Yau
    Cross, Michael
    Kahl, Christoph
    Wass, Maxi
    Sayer, Herbert G.
    Brosteanu, Oana
    Niederwieser, Dietger
    Al-Ali, Haifa Kathrin
    BLOOD, 2017, 130
12345